EUVIMEDEUVIMED entdecken
Crossref

Adagrasib (Krazati) for NSCLC (online only)

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adagrasib (Krazati – Mirati Therapeutics), a RAS GTPase family inhibitor, has received accelerated approval from the FDA for oral treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who received at least one prior systemic therapy. Accelerated approval was based on the objective response rate and duration of response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPyrimidinesAcetonitrilesPiperazines

Stichwörter der Autor:innen

Krazatiadagrasibadverse effectsdosagedrug interactionsefficacylactationlung cancerpregnancysafety

Substanzen

PyrimidinesAcetonitrilesadagrasibPiperazines

Zitieren

APA

(2023). Adagrasib (Krazati) for NSCLC (online only). The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668f

Vancouver

Adagrasib (Krazati) for NSCLC (online only). The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668f

BibTeX
@article{euvimed2023,
  title = {Adagrasib (Krazati) for NSCLC (online only)},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668f}
}
Kostenlos starten →